S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CELC

Celcuity (CELC) Stock Price, News & Analysis

$21.60
+3.44 (+18.94%)
(As of 03/28/2024 ET)
Today's Range
$17.67
$22.19
50-Day Range
$14.35
$21.60
52-Week Range
$8.39
$22.19
Volume
605,554 shs
Average Volume
219,042 shs
Market Capitalization
$522.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.00

Celcuity MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
34.3% Upside
$29.00 Price Target
Short Interest
Bearish
8.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Celcuity in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$4,952 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.76) to ($2.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.62 out of 5 stars

Medical Sector

525th out of 938 stocks

Medical Laboratories Industry

12th out of 20 stocks

CELC stock logo

About Celcuity Stock (NASDAQ:CELC)

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

CELC Stock Price History

CELC Stock News Headlines

Q4 2023 Celcuity Inc Earnings Call
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Recap: Celcuity Q4 Earnings
CELC Apr 2024 20.000 call
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
Celcuity (NASDAQ: CELC)
See More Headlines
Receive CELC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:CELC
Fax
N/A
Employees
45
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.00
High Stock Price Target
$40.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+34.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-40,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.17 per share

Miscellaneous

Free Float
18,322,000
Market Cap
$522.72 million
Optionable
Optionable
Beta
0.74
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Brian F. Sullivan (Age 62)
    Co-Founder, Chairman & CEO
    Comp: $105.77k
  • Dr. Lance G. Laing Ph.D. (Age 62)
    Co-Founder, Chief Science Officer, VP, Secretary & Director
    Comp: $325.38k
  • Ms. Vicky Hahne (Age 58)
    Chief Financial Officer
    Comp: $210k
  • Dr. John R. MacDonald Dabt (Age 69)
    Ph., Ph.D., Senior Vice President of R&D
  • Ms. Sheri Smith
    Acting Head of Clinical Operations
  • Mr. Igor Gorbatchevsky M.D.
    Chief Medical Officer
  • Mr. Eldon C. Mayer III (Age 63)
    M.B.A., Chief Commercial Officer

CELC Stock Analysis - Frequently Asked Questions

Should I buy or sell Celcuity stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CELC shares.
View CELC analyst ratings
or view top-rated stocks.

What is Celcuity's stock price target for 2024?

4 equities research analysts have issued twelve-month target prices for Celcuity's shares. Their CELC share price targets range from $24.00 to $40.00. On average, they anticipate the company's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price.
View analysts price targets for CELC
or view top-rated stocks among Wall Street analysts.

How have CELC shares performed in 2024?

Celcuity's stock was trading at $14.57 on January 1st, 2024. Since then, CELC shares have increased by 48.2% and is now trading at $21.60.
View the best growth stocks for 2024 here
.

When is Celcuity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CELC earnings forecast
.

How were Celcuity's earnings last quarter?

Celcuity Inc. (NASDAQ:CELC) announced its quarterly earnings results on Monday, November, 13th. The company reported ($0.83) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by $0.09. During the same quarter in the previous year, the business posted ($0.75) earnings per share.

What other stocks do shareholders of Celcuity own?
When did Celcuity IPO?

Celcuity (CELC) raised $18 million in an IPO on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

Who are Celcuity's major shareholders?

Celcuity's stock is owned by a variety of retail and institutional investors. Top institutional investors include Commodore Capital LP (7.25%), Perceptive Advisors LLC (6.12%), Vanguard Group Inc. (3.39%), Vanguard Group Inc. (3.39%), Northern Trust Corp (0.76%) and PFM Health Sciences LP (0.65%). Insiders that own company stock include Brian F Sullivan, David Dalvey, Richard E Buller and Richard Nigon.
View institutional ownership trends
.

How do I buy shares of Celcuity?

Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CELC) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners